About This Trial
mRNA therapy encoding PCCA and PCCB enzymes for this life-threatening metabolic disorder.
Primary Endpoints
- Safety
- Reduction in metabolic decompensation events
Latest Update
January 2026
All 12 patients in dose-escalation phase showed reduced plasma biomarkers. No serious adverse events reported.